



March 4, 2011

## **Peregrine to Report Third Quarter Fiscal Year 2011 Financial Results After Market Close on March 11, 2011**

TUSTIN, CA -- (MARKET WIRE) -- 03/04/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the third quarter fiscal year 2011 on March 11, 2011 after market close and will host a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT). Peregrine's senior management will discuss financial results for the third quarter ended January 31, 2011 of fiscal year 2011 and will review its clinical development programs.

- To listen to the live webcast or access the archived webcast available for 30 days, please visit: <http://ir.peregrineinc.com/events.cfm>.
- To listen to the conference call, please call (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call. A replay of the call will be available starting approximately two hours after the conclusion of the call through March 25, 2011 by calling (800) 642-1687 or (706) 645-9291 and using passcode 42778420.

### *About Peregrine Pharmaceuticals*

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ([www.avidbio.com](http://www.avidbio.com)), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at [www.peregrineinc.com](http://www.peregrineinc.com).

Contact:

Amy Figueroa

Peregrine Pharmaceuticals

(800) 987-8256

[info@peregrineinc.com](mailto:info@peregrineinc.com)

Source: Peregrine Pharmaceuticals

News Provided by Acquire Media